MedTrace Logo

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge and at Post-discharge Check-up: Quasi-experimental Clinical Uncontrolled Trial (PHAROS)

NCT04930302 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2023-10-11

No results posted yet for this study

Summary

This project aims to assess the impact of pharmaceutical care in collaboration with physicians on prevalence of DRPs at hospital admission and discharge in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

The key focus area of this project will be the identification of DRPs, their occurrence and type. As a part of further research, the investigators want to analyze the a) acceptance rate of pharmaceutical intervention by physicians. Proportion of accepted interventions by physicians was calculated and b) patients' understanding of his/her pharmacotherapy assessed on a three-point scale at hospital admission.

Hypothesis:

Null hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge does not reduce prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

Alternative hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge reduces prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

Primary outcomes:

Change in the prevalence rate of DRPs at hospital admission vs. hospital discharge.

Secondary outcomes:

1. acceptance rate of pharmaceutical intervention by physician
2. patients' understanding of his/her pharmacotherapy

Conditions

  • Medication Errors and Other Product Use Errors and Issues

Sponsors & Collaborators

  • National Institute of Cardiovascular Diseases, Slovakia

    lead OTHER

Principal Investigators

  • Slavka Porubcova, PharmDr. · National Institute of Cardiovascular Diseases

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-30
Completion
2023-10-01

Countries

  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930302 on ClinicalTrials.gov